VC Short Alertgy Overview

A DISRUPTIVE TECHNOLOGY FOR DIABETICS AND THOSE AT RISK

August 29, 2016

Transforming Health Through Innovation 1© 2016 Alertgy LLC Proprietary and Confidential

Transforming Health Through Innovation

Transforming Health Through Innovation 2

Alertgy was founded in 2016 to develop and commercialize a noninvasive blood sugar monitor and also enabling continuous

monitoring to:

#StopThePrick!

Unique, Multi-billion Dollar OpportunityTechnology

•New sensor technology

•Miniaturization

•New materials

•Increased computational power

Market

•Diabetes and prediabetes populations growing

•Closer monitoring/better control reduces healthcare costs

•Current products not ideal for patient acceptance (blood stick)

•Increased use of smart phones

OUTCOME

•New technology that will disrupt current approaches

•Time to market 3 years

•Investment payments align to milestones to mitigate risk

•.> 100% revenue ROI in year 4 (multi-billion dollar revenue by end of year 4)


The Right People to Make it Happen!


Marc Rippen CEO & Founder Engineer / Scientist

Craig Nelson COOManufacturing Guru

Dr. Helga Rippen CMOMD, PhD, MPH, FACPM

© 2016 Alertgy LLC Proprietary and Confidential

“I have been involved in healthcare for over 20 years and know when a new technology can make a difference! Alertgy’s non-invasive blood sugar monitor is technically possible and will revolutionize the care diabetics and prediabetics receive.”

“I have been providing cutting edge solutions for the military for over 20 years. My wife is a diabetic and my concern for her health has redirected my focus to solving her challenges. We have a highly viable technological approach and are poised to disrupt the market.”

“I have been setting designing automated mass production lines for flexible micro electronic products for over 30 years. I am a diabetic and I know this technology will drastically improve my life quality. It will also help my doctor better assist me in maintaining my health.


Non-InvasiveGlucose Sensor

Array A/D

SoCProcessor

WiFI

BatteryPowered

Base Circuit Architecture of Wristband Sensor System

AnalogPre/Post

conditioningInterface

D/A

• The Noninvasive Glucose Wireless Monitor Alert System converts electrical signals generated by the sensors in a wrist band into a data file, communicating the data in a secure encrypted mode using wireless Bluetooth protocol to a smartphone.

• The smartphone app will conduct Multivariate Analysis to normalize the blood sugar data to provide accurate real time blood sugar levels and display them on screen on demand and/or to alert user when blood sugar levels are too high or low.

• Based on blood sugar levels detected, the app can alert the user, immediate family, and physicians as programmed by the user.

• The Alertgy app will be able to operate on both Android and Apple platforms.

Technology Overview

#StopThePrick!

Base Technology is Proven

• The Alertgy non-invasive continuous glucose monitoring system is based on impedance spectroscopy, which is very well documented in numerous published sources in the literature.

• In the proof of principal study the sensor used in the experiments is the size of a finger tip worked to create an open resonant circuit coupled to the skin and a circuit to perform an impedance measurement.

• The results of testing with the gen 1 finger tip sensor are presented in a plot comparison with the standard prick and stick glucometer method on the next page of this presentation.

• The results of this first series of experiments are considered as a proof of concept for this novel non-invasive monitoring approach.


#StopThePrick!

Dielectric Sensor Versus One Touch


Composite Glucometer Calibration Results

50

70

90

110

130

150

170

50 70 90 110 130 150 170

OneTouch Standard

Pre

dic

ted

Va

lue


#StopThePrick!

Competition


METHOD LEVEL OF INTRUSIVENESSMONITORING

RATE MONTITORING MODE COSTSmart Phone

Alert

Finger Prick Meter and Stick High (finger prick) 8 Times Daily Manual 6 dollars a day No

Dexcom chip (7 day)High (Injected chip / needle sub-cue) Continous Automatic

16 dollars a day Yes

Watch Electrophorsis (<50% can use) High (micropricks can cause rash) Continous Automatic

20 dollars a day No

Optical SpectroscopyMedium (Clap on ear in finger web) 8 Times Daily Manual 5 dollars a day No

Alertgy Dielectric Sensor (30 day) None (wristband) Continuous Automatic 4 dollars a day Yes

Echo Star (15 day)Medium (patch and abrasion of skin) Continuous Automatic 7 dollars a day Yes


Potential US Market Size of120 Million and Growing

Estimated 9.3% of the US adult population have diabetes and 37% are pre-diabetic

Diagnosed**, 22,000,000,

19%

Undiagnosed*, 8,100,000, 7%

Gestational diabetes,

366,705, 0%

Prediabetics, 86,000,000,

72%

Quantifiable self,

2,500,000, 2%


*2012 numbers, CDC; **2014 numbers for diagnosed; *** WHO


International Market – 422 million; 8.5% of world population and growing***

* 2010, US, CDC, US** http://www.medscape.com/viewarticle/809547

Economic Cost Estimated to be $245 billion/year*


Lifetime, direct health care cost for one patient: $55,000 -$130,000**


http://www.medscape.com/viewarticle/809547

Diabetics have a Decreased Quality of Life, Higher Complication Rates, and Shorter

Life Expectancy

• 7th leading cause of death in the US• 28.5% of diabetics older than 40 have diabetic retinopathy (vision loss)• 44% of kidney failure caused by diabetes• Heart attack rates 1.8 times higher for diabetics, deaths 1.7 time higher• Stroke hospitalization rates 1.5 times higher for diabetics• 60% of non-traumatic lower limb amputations (20 and older) are diabetics


Best Practices: Clinical Blood Glucose Goals for Patients to Follow*

• Goals:

– Pre-meal 80-130 mg/dL;

– Post-meal < 180 mg/dL [1-2 hrsafter beginning of meal]


*http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf


• High/Low levels

– Low <= 70 mg/dL

– High• Pre-meal >130

• Post-meal >=180

Prototype to Market Over Three Year Time Period


Phase I Gen 2 Prototype

Develop Gen / Test 2 Prototype:

• Test with other sensors

• Enhance technology

• Develop / build gen 2 Prototype for wristband form factor.

• Preliminary testing with patients for final sensor selection

Gen 2 Product Manufacture

Gen 2 :

• Complete Generation 2: Enhancements

• Complete Software/ hardware

• ASIC Design / Build

• Manufacture, test beta product

Phase II Market Launch

Introduce to Market

• Clinical Trials

• FDA approval

• Quality control (device)

• Consumer/Patient data

• Correlation algorithm

• Sensitivity/Specificity (alert)

• Continuous monitoring performance

• Consumer views


Strategic Partners


Moving Forward

Alertgy is seeking investment for equity.

Revenue: $ 2,000 million in year 4

Profit: 30 %

Funding goal: $ 20 million

ROI: 300 %


Questions?


VC Short Alertgy Overview

Documents